Search Results - "Bloehdorn, J."

High-dose methotrexate-based immuno-chemotherapy for elderly primary CNS lymphoma patients (PRIMAIN study) by Fritsch, K, Kasenda, B, Schorb, E, Hau, P, Bloehdorn, J, Möhle, R, Löw, S, Binder, M, Atta, J, Keller, U, Wolf, H-H, Krause, S W, Heß, G, Naumann, R, Sasse, S, Hirt, C, Lamprecht, M, Martens, U, Morgner, A, Panse, J, Frickhofen, N, Röth, A, Hader, C, Deckert, M, Fricker, H, Ihorst, G, Finke, J, Illerhaus, G

“…To investigate immuno-chemotherapy for elderly immuno-competent patients (⩾65 years) with newly diagnosed primary central nervous system lymphoma, we conducted…”
Get full text

Impact of serum storage conditions on microRNA stability by Grasedieck, S, Schöler, N, Bommer, M, Niess, J H, Tumani, H, Rouhi, A, Bloehdorn, J, Liebisch, P, Mertens, D, Döhner, H, Buske, C, Langer, C, Kuchenbauer, Florian

Get full text

High-dose chemotherapy with autologous haematopoietic stem cell support for relapsed or refractory primary CNS lymphoma: a prospective multicentre trial by the German Cooperative PCNSL study group by Kasenda, B, Ihorst, G, Schroers, R, Korfel, A, Schmidt-Wolf, I, Egerer, G, von Baumgarten, L, Röth, A, Bloehdorn, J, Möhle, R, Binder, M, Keller, U, Lamprecht, M, Pfreundschuh, M, Valk, E, Fricker, H, Schorb, E, Fritsch, K, Finke, J, Illerhaus, G

“…To investigate safety and efficacy of high-dose chemotherapy followed by autologous stem cell transplantation (HCT-ASCT) in relapsed/refractory (r/r) primary…”
Get full text

Lamin B1 regulates somatic mutations and progression of B-cell malignancies by Klymenko, T, Bloehdorn, J, Bahlo, J, Robrecht, S, Akylzhanova, G, Cox, K, Estenfelder, S, Wang, J, Edelmann, J, Strefford, J C, Wojdacz, T K, Fischer, K, Hallek, M, Stilgenbauer, S, Cragg, M, Gribben, J, Braun, A

“…Somatic hypermutation (SHM) is a pivotal process in adaptive immunity that occurs in the germinal centre and allows B cells to change their primary DNA…”
Get full text

The regulatory interaction of EVI1 with the TCL1A oncogene impacts cell survival and clinical outcome in CLL by Vasyutina, E, Boucas, J M, Bloehdorn, J, Aszyk, C, Crispatzu, G, Stiefelhagen, M, Breuer, A, Mayer, P, Lengerke, C, Döhner, H, Beutner, D, Rosenwald, A, Stilgenbauer, S, Hallek, M, Benner, A, Herling, M

“…Dysregulated T-cell leukemia/lymphoma-1A (TCL1A), a modulator in B-cell receptor (BCR) signaling, is causally implicated in chronic lymphocytic leukemia (CLL)…”
Get full text

Frequent evolution of copy number alterations in CLL following first-line treatment with FC(R) is enriched with TP53 alterations: results from the CLL8 trial by Edelmann, J, Tausch, E, Landau, D A, Robrecht, S, Bahlo, J, Fischer, K, Fink, A M, Bloehdorn, J, Holzmann, K, Böttcher, S, Werner, L, Kneba, M, Gribben, J G, Neuberg, D S, Wu, C J, Hallek, M, Döhner, H, Stilgenbauer, S

Get full text

Targeting transcription-coupled nucleotide excision repair overcomes resistance in chronic lymphocytic leukemia by Lohmann, G, Vasyutina, E, Bloehdorn, J, Reinart, N, Schneider, J I, Babu, V, Knittel, G, Crispatzu, G, Mayer, P, Prinz, C, Muenzner, J K, Biersack, B, Efremov, D G, Chessa, L, Herling, C D, Stilgenbauer, S, Hallek, M, Schobert, R, Reinhardt, H C, Schumacher, B, Herling, M

“…Treatment resistance becomes a challenge at some point in the course of most patients with chronic lymphocytic leukemia (CLL). This applies to…”
Get full text

CLINICAL PRESENTATION AND MOLECULAR CHARACTERISTICS OF CUTANEOUS DLBCL by Bloehdorn, J., Weissinger, S.E., Sindrilaru, A., Peters, T., Möller, P., Marienfeld, R., Viardot, A.

Get full text

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: a comparison of Nordic MCL2, HOVON-45, and European MCL Younger trials by Hoster, E, Geisler, C H, Doorduijn, J, van der Holt, B, Walewski, J, Bloehdorn, J, Ribrag, V, Salles, G, Hallek, M, Pott, C, Szymczyk, M, Kolstad, A, Laurell, A, Räty, R, Jerkeman, M, van't Veer, M, Kluin-Nelemans, J C, Klapper, W, Unterhalt, M, Dreyling, M, Hermine, O

Get full text

GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORABMUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY Best abstract submitted by a young investigator / travel grant recipient by Tausch, E., Bahlo, J., Robrecht, S., Schneider, C., Bloehdorn, J., Schrell, S., Galler, C., Al‐Sawaf, O., Fink, A., Eichhorst, B., Kreuzer, K., Tandon, M., Humphrey, K., Jiang, Y., Schary, W., Porro Lurà, M., Döhner, H., Fischer, K., Hallek, M., Stilgenbauer, S.

Get full text

Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG) by Jaramillo, Sonia, Agathangelidis, Andreas, Schneider, Christof, Bahlo, Jasmin, Robrecht, Sandra, Tausch, Eugen, Bloehdorn, Johannes, Hoechstetter, Manuela, Fischer, Kirsten, Eichhorst, Barbara, Goede, Valentin, Hallek, Michael, Döhner, Hartmut, Rosenquist, Richard, Ghia, Paolo, Stamatopoulos, Kostas, Stilgenbauer, Stephan

“…Almost one-third of all patients with chronic lymphocytic leukemia (CLL) express stereotyped B cell receptor immunoglobulins (BcR IG) and can be assigned to…”
Get full text

Frequent evolution of copy number alterations in CLL following first-line treatment with FC by Robrecht, S, Werner, L, Stilgenbauer, S, Fischer, K, Fink, A.M, Landau, D.A, Wu, C.J, Döhner, H, Hallek, M, Bahlo, J, Kneba, M, Edelmann, J, Tausch, E, Böttcher, S, Gribben, J.G, Bloehdorn, J, Holzmann, K, Neuberg, D.S

Get full text

GENETIC MARKERS AND OUTCOME WITH FRONT LINE OBINUTUZUMAB PLUS EITHER CHLORAMBUCIL OR VENETOCLAX ‐ UPDATED ANALYSIS OF THE CLL14 TRIAL by Tausch, E, Schneider, C, Yosifov, D, Robrecht, S, Zhang, C, Al‐Sawaf, O, Eichhorst, B, Fink, A.‐M, Bloehdorn, J, Kreuzer, K.‐A, Tandon, M, Jiang, Y, Kim, S. Y, Porro Lura, M, Döhner, H, Fischer, K, Hallek, M, Stilgenbauer, S

Get full text

Additional Genetic High-Risk Features Such As 11q Deletion, 17p Deletion, and V3-21 Usage Characterize Discordance of ZAP-70 and VH Mutation Status in Chronic Lymphocytic Leukemia by Kröber, Alexander, Bloehdorn, Johannes, Hafner, Sebastian, Bühler, Andreas, Seiler, Till, Kienle, Dirk, Winkler, Dirk, Bangerter, Markus, Schlenk, Richard F, Benner, Axel, Lichter, Peter, Döhner, Hartmut, Stilgenbauer, Stephan

“…Immunoglobulin heavy chain variable-region (VH) gene mutation status and zeta-associated protein 70 (ZAP-70) expression are correlated in chronic lymphocytic…”
Get full text

Prognostic impact of common chronic lymphocytic leukemia stereotyped subsets: analysis within prospective clinical trials of the German CLL Study Group (GCLLSG) by Segura, SJ, Agathangelidis, A, Schneider, C, Bahlo, J, Robrecht, S, Tausch, E, Bloehdorn, J, Hoechstetter, M, Fischer, K, Eichhorst, B, Goede, V, Hallek, M, Dohner, H, Brandell, RR, Ghia, P, Stamatopoulos, K, Stilgenbauer, S

Get full text

S105 GENETIC MARKERS AND OUTCOME IN THE CLL14 TRIAL OF THE GCLLSG COMPARING FRONT LINE OBINUTUZUMAB PLUS CHLORAMBUCIL OR VENETOCLAX IN PATIENTS WITH COMORBIDITY by Tausch, E., Bahlo, J., Robrecht, S., Schneider, C., Bloehdorn, J., Schrell, S., Galler, C., Al‐Sawaf, O., Fink, A.‐M., Eichhorst, B., Kreuzer, K.‐A., Tandon, M., Humphrey, K., Jiang, Y., Schary, W., Porro Lurà, M., Döhner, H., Fischer, K., Hallek, M., Stilgenbauer, S.

“…Background: Genomic aberrations, IGHV mutation status and mutations in genes such as TP53 are established prognostic factors in CLL in the context of…”
Get full text

Total body irradiation after high-dose cytarabine in mantle cell lymphoma: A comparison of Nordic MCL2, HOVON-45, and European MCLYounger trials by Hoster, E, Geisler, C H, Doorduijn, J, van der Holt, B, Walewski, J, Bloehdorn, J, Ribrag, V, Salles, G, Hallek, M, Pott, C, Szymczyk, M, Kolstad, A, Laurell, A, Räty, R, Jerkeman, Mats, Van't Veer, M, Kluin-Nelemans, J C, Klapper, W, Unterhalt, M, Dreyling, M, Hermine, O

Get full text